A Glycoconjugate Vaccine for Neisseria meningitidis Induces Antibodies in Human Infants That Afford Protection against Meningococcal Bacteremia in a Neonate Rat Challenge Model
AUTOR(ES)
Mountzouros, Kenneth T.
FONTE
American Society for Microbiology
RESUMO
The functional activities of serum samples from human infants immunized with a glycoconjugate vaccine for Neisseria meningitidis serogroup C were assessed in a complement-mediated antibody-dependent serum bactericidal assay (SBA) and in a neonate rat model of protection from bacteremia. Selective serum samples from individual human infants were combined to make a panel of 11 serum pools to obtain a sufficient volume for testing. Each pool was assayed (i) for the anti-N. meningitidis serogroup C capsular polysaccharide (PS) immunoglobulin G (IgG) concentration as determined by reactivity in a direct-binding enzyme-linked immunosorbent assay, (ii) for bactericidal activity against N. meningitidis serogroup C strain C11, and (iii) for the ability to reduce bacteremia after passive transfer into a neonate rat model. Representative serum samples from infants who were not previously immunized with any N. meningitidis serogroup C vaccine served as a negative control. The prepared serum pools ranged in antibody concentration from 0.18 to 17.31 μg of IgG specific for N. meningitidis serogroup C PS per ml. For this serum panel, a direct relationship between concentrations of anti-N. meningitidis serogroup C PS-specific IgG and serum SBA titers (r = 0.9960) was observed. Passive transfer to neonate rats demonstrated the ability of postimmunization serum samples to significantly reduce (≥2-log10 reduction compared to control animals) the level of bacteremia following a challenge. Of 79 neonate rats that received ≥0.031 μg of human infant anti-N. meningitidis serogroup C PS IgG, 75 (94.9%) had a ≥2-log10 reduction in bacteremia, whereas of the animals that received <0.031 μg of antigen-specific IgG, 10.3% (4 of 39 rats) showed a ≥2-log10 reduction in bacteremia. It was concluded that the anti-N. meningitidis serogroup C PS IgG antibody induced by this glycoconjugate vaccine had in vitro functional activity (as determined by a SBA) and also afforded protection against meningococcal bacteremia in an animal model.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=133014Documentos Relacionados
- Protection Against Meningococcal Challenge Afforded Mice After Immunization with Typhoid-Paratyphoid Vaccine USP
- Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model.
- Monoclonal antibodies against Neisseria meningitidis lipopolysaccharide.
- Recombinant Neisseria meningitidis Transferrin Binding Protein A Protects against Experimental Meningococcal Infection
- Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis.
